Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma
Adult
Male
liquid biopsy
Squamous Cell Carcinoma of Head and Neck
Liquid Biopsy
Chemoradiotherapy
Middle Aged
chemotherapy
head and neck squamous cell carcinoma
Microbiology
QR1-502
3. Good health
03 medical and health sciences
0302 clinical medicine
Head and Neck Neoplasms
Pathology
Biomarkers, Tumor
RB1-214
Humans
circulating free dna
Female
real-time pcr
Cell-Free Nucleic Acids
DOI:
10.4103/ijpm.ijpm_28_20
Publication Date:
2020-10-27T16:47:34Z
AUTHORS (8)
ABSTRACT
Liquid biopsy has moved from bench to bedside as a non-invasive biomarker for early diagnosis and monitoring treatment response.This study investigated the role of circulating free DNA (cfDNA) as a diagnostic marker in locally advanced head and neck squamous cell carcinoma (HNSCC) and in monitoring response to chemoradiation therapy.Serum was collected from treatment naïve, histopathologically diagnosed tumors in 24 HNSCC cases and 16 normal controls. CfDNA levels were quantified using β globin gene amplification.The cfDNA level was significantly elevated in HNSCC (992.67 ± 657.43 ng/mL) as compared to healthy controls (60.65 ± 30.42 ng/mL, P = <0.001). The levels of cfDNA did not significantly correlate with TNM stage, lymph node involvement and grade. In responders, percentage decrease in cfDNA levels was 9.57% and 29.66%, whereas in nonresponders percentage increase was 13.28% and 24.52% at the end of three months of follow-up.Our study adds to the evidence that cfDNA levels are significantly higher in HNSCC cases and provides some evidence that levels increase with tumor progression. CfDNA may be a promising prospective non-invasive marker to predict response in patients undergoing chemo-radiotherapy.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (27)
CITATIONS (9)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....